论文部分内容阅读
目的:分析环磷酰胺治疗原发性胆汁性肝硬化患者的临床疗效。方法:选取医院自2009年2月—2014年2月期间收治的原发性胆汁性肝硬化患者94例,将其平均分为观察组和对照组;观察组予环磷酰胺治疗,对照组予熊去氧胆酸治疗,观察两组患者治疗后的临床疗效和治疗前后总胆红素的变化以及用药后不良反应的发生情况。结果:观察组患者治疗的显效率和总有效率、治疗前后总胆红素的改善程度均高于对照组(P<0.05);观察组患者用药后不良反应的发生率低于对照组(P<0.05)。结论:环磷酰胺对原发性胆汁性肝硬化患者的临床疗效果显著,有效降低了不良反应的发生率。
Objective: To analyze the clinical efficacy of cyclophosphamide in the treatment of patients with primary biliary cirrhosis. Methods: A total of 94 patients with primary biliary cirrhosis who were hospitalized from February 2009 to February 2014 were selected and divided into observation group and control group. The observation group was treated with cyclophosphamide and the control group Ursodeoxycholic acid treatment, observation of two groups of patients after treatment, the clinical efficacy and change of total bilirubin before and after treatment and the incidence of adverse reactions. Results: The effective rate and total effective rate of the treatment group were significantly higher than those of the control group before and after treatment (P <0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05). Conclusion: The clinical effect of cyclophosphamide on patients with primary biliary cirrhosis is significant, effectively reducing the incidence of adverse reactions.